STERIS plc
Consolidated Condensed Statements of Operations
(in millions, except per share data)

	Three Months Ended June 30,	
	2026	**2025**
	(Unaudited)	**(Unaudited)**
Revenues	**$ 1,492.7**	$ 1,391.1
Cost of revenues	**808.6**	763.1
Gross profit	**684.2**	628.0
Operating expenses:		
Selling, general, and administrative	**369.7**	353.8
Research and development	**28.6**	26.4
Restructuring expenses	**—**	1.8
Total operating expenses	**398.3**	382.0
Income from operations	**285.8**	246.0
Non-operating expenses, net:		
Interest expense	**15.8**	15.9
Interest and miscellaneous income	**(3.1)**	(1.8)
Other income, net	**(0.3)**	—
Total non-operating expenses, net	**12.3**	14.1
Income before income tax expense	**273.5**	231.9
Income tax expense	**72.5**	53.9
Net income	**$ 201.0**	$ 178.0
Less: Net income attributable to noncontrolling interests	**0.9**	0.6
Net income attributable to shareholders	**$ 200.1**	**$ 177.4**
Earnings per ordinary share (EPS)		
Basic	**$ 2.05**	$ 1.80
Diluted	**$ 2.04**	$ 1.79
Cash dividends declared per share ordinary outstanding	**$ 0.63**	$ 0.57
Weighted average number of shares outstanding used in EPS computation:		
Basic number of shares outstanding	**97.6**	98.4
Diluted number of shares outstanding	**97.9**	98.8

STERIS plc
Consolidated Condensed Balance Sheets
(in millions)

	June 30, 2026	March 31, 2026
	(Unaudited)	
Assets		
Current assets:		
Cash and cash equivalents	**$ 482.3**	$ 439.6
Accounts receivable, net	**1,013.2**	1,092.8
Inventories, net	**712.1**	631.8
Prepaid expenses and other current assets	**238.2**	230.4
Total current assets	**2,445.8**	2,394.6
Property, plant, and equipment, net	**2,171.7**	2,161.2
Lease right-of-use assets, net	**150.8**	155.2
Goodwill	**4,189.2**	4,194.8
Intangibles, net	**1,563.5**	1,620.0
Other assets	**215.1**	211.4
Total assets	**$ 10,736.1**	$ 10,737.2
Liabilities and equity		
Current liabilities:		
Accounts payable	**$ 344.1**	$ 338.8
Short-term indebtedness	**243.4**	118.9
Other current liabilities	**695.7**	687.4
Total current liabilities	**1,283.3**	1,145.0
Long-term indebtedness	**1,650.2**	1,812.8
Other liabilities	**581.3**	582.1
Total equity	**7,221.3**	7,197.2
Total liabilities and equity	**$ 10,736.1**	$ 10,737.2

STERIS plc

Segment Data

(in millions)

Financial information for each of the segments is presented in the following table. We disclose a measure of segment income that is consistent with the way management operates and views the business. The accounting policies for reportable segments are the same as those for the consolidated Company. Segment income is calculated as the segment's gross profit less direct costs and indirect costs if the resources are dedicated to a single segment. Corporate costs include corporate and administrative functions, public company costs, legacy post-retirement benefits, certain services and facilities related to distribution and research and development that are shared by multiple segments, as well as the benefit of refunds received on tariffs previously paid under the International Economic Emergency Powers Act.

	Three Months Ended June 30,	
	2026	**2025**
	(Unaudited)	**(Unaudited)**
Revenues:		
Healthcare	**$ 1,048.3**	$ 974.7
AST	**297.6**	281.2
Life Sciences	**146.7**	135.2
Total revenues	**$ 1,492.7**	$ 1,391.1
Income (loss) from operations before adjustments:		
Healthcare	**$ 260.2**	$ 235.5
AST	**142.9**	136.7
Life Sciences	**61.8**	58.7
Corporate	**(110.1)**	(114.0)
Total income from operations before adjustments	**$ 354.8**	$ 316.9
Less: Adjustments		
Amortization of acquired intangible assets	**$ 65.3**	$ 67.1
Acquisition and integration related charges	**1.5**	0.5
Tax restructuring costs	**0.3**	0.2
Amortization of inventory and property "step up" to fair value	**1.8**	1.4
Restructuring charges	**—**	1.8
Income from operations	**$ 285.8**	$ 246.0

STERIS plc
Consolidated Condensed Statements of Cash Flows
(in millions)

	Three Months Ended June 30,	
	2026	**2025**
Operating activities:	**(Unaudited)**	**(Unaudited)**
Net income	**$ 201.0**	$ 178.0
Non-cash items	**148.3**	145.8
Changes in operating assets and liabilities	**17.7**	96.2
Net cash provided by operating activities	**367.1**	420.0
Investing activities:		
Purchases of property, plant, equipment, and intangibles	**(87.5)**	(93.6)
Proceeds from the sale of property, plant, equipment, and intangibles	**—**	0.1
Purchases of investments	**(5.0)**	—
Acquisition of businesses, net of cash acquired	**(16.0)**	(15.0)
Net cash used in investing activities	**(108.5)**	(108.5)
Financing activities:		
Payments on Private Placement Senior Notes	**—**	(125.0)
Payments under credit facilities, net	**(37.8)**	(30.5)
Acquisition related deferred or contingent consideration	**(0.1)**	(0.1)
Repurchases of ordinary shares	**(115.5)**	(10.6)
Cash dividends paid to ordinary shareholders	**(61.4)**	(56.2)
Stock option and other equity transactions, net	**1.3**	9.3
Net cash used in financing activities	**(213.5)**	(213.1)
Effect of exchange rate changes on cash and cash equivalents	**(2.3)**	9.6
Increase in cash and cash equivalents	**42.8**	108.0
Cash and cash equivalents at beginning of period	**439.6**	171.7
Cash and cash equivalents at end of period	**$ 482.3**	$ 279.7

The following table presents a financial measure which is considered to be "non-GAAP financial measures" under Securities Exchange Commission rules. Free cash flow is defined by the Company as cash flows from operating activities less purchases of property, plant, equipment and intangibles (capital expenditures) plus proceeds from the sale of property, plant, equipment and intangibles. The Company uses free cash flow as a measure to gauge its ability to pay cash dividends, fund growth outside of core operations, fund future debt principal repayments, and repurchase shares. STERIS's calculation of free cash flows may vary from other companies.

	Three Months Ended June 30,	
	2026	**2025**
	(Unaudited)	(Unaudited)
Calculation of Free Cash Flow:		
Cash flows from operating activities	**$ 367.1**	$ 420.0
Purchases of property, plant, equipment, and intangibles, net	**(87.5)**	(93.6)
Proceeds from the sale of property, plant, equipment, and intangibles	**—**	0.1
Free Cash Flow	**$ 279.6**	$ 326.5

STERIS plc
Non-GAAP Financial Measures
(in millions)

Non-GAAP financial measures are presented with the intent of providing greater transparency to supplemental financial information used by management and the Board of Directors in their financial analysis and operational decision making. These amounts are disclosed so that the reader has the same financial data that management uses with the belief that it will assist investors and other readers in making comparisons to our historical operating results and analyzing the underlying performance of our operations for the periods presented.

Management and the Board of Directors believe that the presentation of these non-GAAP financial measures, when considered along with our U.S. GAAP financial measures and the reconciliation to the corresponding U.S. GAAP financial measures, provides the reader with a more complete understanding of the factors and trends affecting our business than could be obtained absent this disclosure. It is important for the reader to note that the non-GAAP financial measure used may be calculated differently from, and therefore may not be comparable to, a similarly titled measure used by other companies.

To measure the percentage organic revenue growth, the Company removes the impact of acquisitions and divestitures that affect the comparability and trends in revenue. To measure the percentage constant currency organic revenue growth, the impact of changes in currency exchange rates and acquisitions and divestitures that affect the comparability and trends in revenue are removed. The impact of changes in currency exchange rates is calculated by translating current year results at prior year average currency exchange rates.

	Three Months Ended June 30, (unaudited)							
	As reported, U.S. GAAP		Impact of Acquisitions	Impact of Divestitures	Impact of Foreign Currency Movements	U.S. GAAP Growth	Organic Growth	Constant Currency Organic Growth
	2026	2025	2026	2025	2026	2026	2026	2026
Segment revenues:								
Healthcare	**$ 1,048.3**	$ 974.7	**$ 6.9**	**$ —**	**$ 4.2**	**7.6 %**	**6.9 %**	**6.4 %**
AST	**297.6**	281.2	**—**	**—**	**3.2**	**5.8 %**	**5.8 %**	**4.7 %**
Life Sciences	**146.7**	135.2	**—**	**—**	**0.9**	**8.6 %**	**8.6 %**	**7.9 %**
Total	**$ 1,492.7**	$ 1,391.1	**$ 6.9**	**$ —**	**$ 8.4**	**7.3 %**	**6.8 %**	**6.2 %**

	Three Months Ended June 30, (unaudited)									
	Gross Profit		Income from Operations		Income, net of income tax		Net Income attributable to shareholders		Diluted EPS	
	2026	2025	2026	2025	2026	2025	2026	2025	2026	2025
As reported, U.S. GAAP	**$ 684.2**	$ 628.0	**$ 285.8**	$ 246.0	**$ 201.0**	$ 178.0	**$ 200.1**	$ 177.4	**$ 2.04**	$ 1.79
Adjustments:										
Amortization of acquired intangible assets	**1.2**	1.1	**65.3**	67.1						
Acquisition and integration related charges	**0.5**	—	**1.5**	0.5						
Tax restructuring costs	**—**	—	**0.3**	0.2						
Amortization of inventory and property "step up" to fair value	**0.5**	0.5	**1.8**	1.4						
Restructuring charges	**—**	—	**—**	1.8						
Other expense[(1)]					**0.8**	—				
Net impact of adjustments after tax[(2)]					**52.5**	53.8	**53.3**	53.8		
Net EPS impact									**0.55**	0.55
Adjusted	**$ 686.4**	$ 629.6	**$ 354.8**	$ 316.9	**$ 254.3**	$ 231.8	**$ 253.4**	$ 231.2	**$ 2.59**	$ 2.34

[(1)] Includes the amortization of intangible asset basis differences arising from the Company's equity method investment.
[(2)] The tax expense includes both the current and deferred income tax impact of the adjustments.

STERIS plc
Non-GAAP Financial Measures (Continued)
(in millions, except per share data)

FY 2027 Outlook	**Twelve Months Ended March 31, 2027 (Outlook)***
Net income from continuing operations per diluted share	$8.92 - $9.12
Amortization of acquired intangible assets	2.08
Acquisition and integration related charges	0.01
Restructuring charges	0.07
Other unusual items	0.02
Adjusted net income from continuing operations per diluted share	$11.10 - $11.30
Cash flows from operating activities	$1,250.0
Purchases of property, plant, equipment, and intangibles, net	(450.0)
Free Cash Flow	$800.0

* All amounts are estimates.

STERIS plc
Unaudited Supplemental Financial Data
First Quarter Fiscal 2027
For the Periods Ending June 30, 2026 and 2025
(in millions)

	FY 2027	FY 2026
Total Company Revenues	**Q1**	**Q1**
Consumables	**$ 474.0**	$ 435.0
Service	**755.5**	700.6
Total Recurring	**$ 1,229.6**	$ 1,135.6
Capital Equipment	**263.2**	255.5
Total Revenues	**$ 1,492.7**	$ 1,391.1
Ireland Revenues	**$ 29.0**	$ 22.5
Ireland Revenues as a % of Total	**2 %**	2 %
United States Revenues	**$ 1,090.6**	$ 1,025.6
United States Revenues as a % of Total	**73 %**	74 %
International Revenues	**$ 373.2**	$ 342.9
International Revenues as a % of Total	**25 %**	24 %

Segment Data	**FY 2027**	**FY 2026**
	Q1	**Q1**
Healthcare		
Revenues		
Consumables	**$ 391.9**	$ 358.9
Service	**425.9**	$ 388.5
Total Recurring	**$ 817.8**	$ 747.4
Capital Equipment	**230.5**	227.3
Total Healthcare Revenues	**$ 1,048.3**	$ 974.7
Segment Operating Income	**$ 260.2**	$ 235.5
AST		
Revenues		
Service	**$ 296.3**	$ 279.6
Capital Equipment	**1.4**	1.6
Total AST Revenues	**$ 297.6**	$ 281.2
Segment Operating Income	**$ 142.9**	$ 136.7
Life Sciences		
Revenues		
Consumables	**$ 81.5**	$ 75.3
Service	**34.0**	$ 33.3
Total Recurring	**$ 115.5**	$ 108.5
Capital Equipment	**31.3**	26.6
Total Life Sciences Revenues	**$ 146.7**	135.2
Segment Operating Income	**$ 61.8**	$ 58.7
Corporate Operating Loss	**$ (110.1)**	$ (114.0)

Other Data	**FY 2027**	**FY 2026**
	Q1	**Q1**
Healthcare Backlog	**$ 444.0**	$ 403.5
Life Sciences Backlog	**109.9**	111.0
Total Backlog	**$ 553.9**	$ 514.5
As reported, U.S. GAAP Income Tax Rate	**26.5 %**	23.3 %
Adjusted Income Tax Rate	**25.9 %**	23.5 %

This supplemental data is consistent with publicly disclosed information provided in quarterly conference calls, earnings releases and SEC filings, and is subject to all definitions, precautions and limitations contained in those disclosures. Please see the Company's most recent 10-K for definitions (and reconciliation where appropriate) of adjusted measures, backlog, free cash flow and net debt.